Stock listing
NASDAQ:KTTA Pasithea Therapeutics Corp. Stock
Home listing (NASDAQ) of Pasithea Therapeutics Corp.
Follow Pasithea Therapeutics Corp. into a list and get an email when it puts out news.
Share price · NASDAQ:KTTA
$0.479 USD -0.032 (-6.3%)
Close on Nov 20, 2026
- Day range
- $0.470 – $0.515 USDNov 20, 2026
- Volume
- 100,722 sharesNov 20, 2026
- Market cap
- $16.00M USDAt the close on Nov 20, 2026 · price × 33.41M shares outstanding
- 52-week range
- $0.281 – $2.060 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $354,003 USDMedian day 216,400 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:KTTA · Home | $0.479 USD | -0.032 (-6.3%) | 100,722 | $0.483 | $0.515 | $0.470 | $0.511 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:KTTA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.479 | -0.032 | -6.3% | $0.483 | $0.515 | $0.470 | 100,722 | |
| $0.511 | +0.077 | +17.6% | $0.446 | $0.538 | $0.446 | 796,144 | |
| $0.434 | -0.066 | -13.1% | $0.510 | $0.510 | $0.419 | 2,079,830 | |
| $0.500 | -0.022 | -4.2% | $0.520 | $0.520 | $0.434 | 944,208 | |
| $0.522 | +0.002 | +0.4% | $0.565 | $0.580 | $0.466 | 2,353,714 | |
| $0.520 | -0.012 | -2.3% | $0.550 | $0.550 | $0.500 | 198,102 | |
| $0.532 | -0.042 | -7.3% | $0.538 | $0.570 | $0.525 | 235,408 | |
| $0.574 | +0.031 | +5.8% | $0.543 | $0.575 | $0.511 | 473,130 | |
| $0.542 | -0.036 | -6.3% | $0.580 | $0.610 | $0.531 | 235,650 | |
| $0.579 | +0.059 | +11.3% | $0.509 | $0.580 | $0.505 | 428,725 | |
| $0.520 | -0.010 | -1.9% | $0.536 | $0.536 | $0.460 | 659,335 | |
| $0.530 | 0.000 | 0.0% | $0.525 | $0.590 | $0.481 | 2,357,234 | |
| $0.530 | +0.162 | +44.0% | $0.365 | $0.534 | $0.345 | 21,753,807 | |
| $0.368 | -0.002 | -0.5% | $0.385 | $0.399 | $0.350 | 247,648 | |
| $0.370 | 0.000 | 0.0% | $0.359 | $0.389 | $0.359 | 99,800 | |
| $0.370 | -0.023 | -5.9% | $0.381 | $0.407 | $0.350 | 329,700 | |
| $0.393 | -0.004 | -1.0% | $0.391 | $0.400 | $0.369 | 596,800 | |
| $0.397 | -0.003 | -0.8% | $0.395 | $0.425 | $0.371 | 649,100 | |
| $0.400 | -0.005 | -1.2% | $0.396 | $0.412 | $0.372 | 628,900 | |
| $0.405 | -0.040 | -9.0% | $0.450 | $0.471 | $0.345 | 1,533,400 | |
| $0.445 | -0.043 | -8.8% | $0.488 | $0.500 | $0.445 | 378,800 | |
| $0.488 | +0.078 | +19.0% | $0.425 | $0.497 | $0.420 | 774,900 | |
| $0.410 | -0.002 | -0.5% | $0.413 | $0.415 | $0.410 | 38,500 | |
| $0.412 | -0.008 | -1.9% | $0.443 | $0.443 | $0.410 | 18,500 | |
| $0.420 | +0.010 | +2.4% | $0.410 | $0.430 | $0.400 | 209,300 | |
| $0.410 | +0.001 | +0.2% | $0.409 | $0.438 | $0.398 | 20,600 | |
| $0.409 | -0.015 | -3.5% | $0.440 | $0.440 | $0.383 | 616,500 | |
| $0.424 | -0.024 | -5.4% | $0.450 | $0.450 | $0.410 | 60,100 | |
| $0.448 | -0.020 | -4.3% | $0.466 | $0.466 | $0.447 | 80,700 | |
| $0.468 | +0.027 | +6.1% | $0.450 | $0.468 | $0.450 | 60,600 | |
| $0.441 | -0.002 | -0.5% | $0.452 | $0.468 | $0.441 | 56,200 | |
| $0.443 | -0.004 | -0.9% | $0.447 | $0.468 | $0.440 | 132,500 | |
| $0.447 | -0.008 | -1.8% | $0.465 | $0.465 | $0.440 | 64,100 | |
| $0.455 | -0.021 | -4.4% | $0.486 | $0.510 | $0.455 | 84,600 | |
| $0.476 | -0.013 | -2.7% | $0.475 | $0.509 | $0.475 | 59,800 | |
| $0.489 | -0.004 | -0.8% | $0.493 | $0.503 | $0.480 | 12,000 | |
| $0.493 | +0.003 | +0.6% | $0.489 | $0.510 | $0.477 | 60,000 | |
| $0.490 | +0.010 | +2.1% | $0.475 | $0.496 | $0.460 | 141,500 | |
| $0.480 | -0.019 | -3.8% | $0.489 | $0.500 | $0.452 | 151,200 | |
| $0.499 | -0.015 | -2.9% | $0.500 | $0.510 | $0.485 | 94,800 | |
| $0.514 | +0.001 | +0.2% | $0.503 | $0.530 | $0.503 | 105,100 | |
| $0.513 | -0.001 | -0.2% | $0.508 | $0.520 | $0.502 | 113,900 | |
| $0.514 | +0.004 | +0.8% | $0.530 | $0.530 | $0.495 | 165,000 | |
| $0.510 | -0.014 | -2.7% | $0.510 | $0.517 | $0.495 | 67,600 | |
| $0.524 | +0.017 | +3.4% | $0.525 | $0.550 | $0.488 | 483,200 | |
| $0.507 | +0.017 | +3.5% | $0.490 | $0.514 | $0.474 | 238,000 | |
| $0.490 | -0.010 | -2.0% | $0.500 | $0.510 | $0.490 | 79,800 | |
| $0.500 | -0.010 | -2.0% | $0.498 | $0.529 | $0.491 | 280,400 | |
| $0.510 | -0.020 | -3.8% | $0.523 | $0.549 | $0.510 | 135,700 | |
| $0.530 | -0.010 | -1.9% | $0.531 | $0.552 | $0.520 | 141,700 | |
| $0.540 | -0.030 | -5.3% | $0.570 | $0.576 | $0.520 | 246,900 | |
| $0.570 | -0.029 | -4.8% | $0.599 | $0.599 | $0.551 | 210,200 | |
| $0.599 | +0.019 | +3.3% | $0.587 | $0.600 | $0.580 | 267,300 | |
| $0.580 | 0.000 | 0.0% | $0.580 | $0.593 | $0.570 | 222,700 | |
| $0.580 | 0.000 | 0.0% | $0.580 | $0.595 | $0.575 | 124,400 | |
| $0.580 | +0.017 | +3.0% | $0.560 | $0.595 | $0.550 | 225,700 | |
| $0.563 | -0.011 | -1.9% | $0.557 | $0.578 | $0.550 | 216,400 | |
| $0.574 | +0.014 | +2.5% | $0.573 | $0.586 | $0.550 | 449,800 | |
| $0.560 | +0.005 | +0.9% | $0.574 | $0.604 | $0.534 | 483,900 | |
| $0.555 | -0.015 | -2.6% | $0.576 | $0.577 | $0.549 | 66,900 | |
| $0.570 | +0.010 | +1.8% | $0.569 | $0.580 | $0.531 | 94,700 | |
| $0.560 | +0.055 | +10.9% | $0.533 | $0.571 | $0.525 | 223,840 | |
| $0.505 | -0.034 | -6.3% | $0.523 | $0.573 | $0.490 | 339,046 | |
| $0.539 | +0.069 | +14.7% | $0.489 | $0.539 | $0.480 | 301,500 | |
| $0.470 | -0.020 | -4.1% | $0.485 | $0.487 | $0.470 | 108,000 |
Splits
1 split · NASDAQ:KTTA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation |
- Ticker
- NASDAQ:KTTA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 13, 2026
Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis Conference
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 20 slides
Latest news
Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis Conference
Nov 13, 2026
Closed $0.522 (+0.4%) on Nov 13, 2026
Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)
Nov 3, 2026
Closed $0.53 (+44.0%) on Nov 3, 2026
Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026
Oct 28, 2026
Closed $0.37 (-5.9%) on Oct 29, 2026
Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
Oct 23, 2026
Closed $0.405 (-9.0%) on Oct 23, 2026
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
Sep 14, 2026
Closed $0.51 (-3.8%) on Sep 14, 2026
Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
Sep 3, 2026
Closed $0.58 (0.0%) on Sep 4, 2026
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
Jul 21, 2026
Closed $0.455 (-3.9%) on Jul 21, 2026
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Jul 8, 2026
Closed $0.512 (-1.5%) on Jul 8, 2026
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion
Jun 30, 2026
Closed $0.515 (-2.1%) on Jun 30, 2026
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
Jun 16, 2026
Closed $0.51 (-8.9%) on Jun 16, 2026
Pasithea Therapeutics Corp. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 23 in the last 12 months · 110 in all · newest Nov 13, 2026 · oldest 2021
- Decks
- 4 decks · latest September 2026
Where Pasithea Therapeutics Corp. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:KTTA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:KTTA | BOATS | United States | USD |
Valuation
Price/book 0.4× against a median of 1.7×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$25.22M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- −0.1×
- Price/book
- 0.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.97
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Pasithea Therapeutics Corp. · NASDAQ:KTTA | US$16.00M | −US$25.22M | n/a | n/a | −0.1× | 0.4× | n/a | 0.0× | 0.97 |
| SynCore Biotechnology Co., Ltd. · TPEX:4192 | US$16.80M | US$12.38M | n/a | 15.6× | n/a | 2.5× | −178.5% | 0.0× | n/a |
| Initiator Pharma A/S · OMXSTO:INIT | US$16.74M | US$15.65M | n/a | n/a | n/a | 13.4× | n/a | 1.1× | n/a |
| Neurotech International Ltd. · ASX:NTI | US$16.63M | US$15.06M | n/a | n/a | n/a | 41.1× | n/a | 0.0× | n/a |
| Akari Therapeutics PLC · NASDAQ:AKTX | US$16.41M | US$10.66M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.49 |
| Lipocine Inc. · NASDAQ:LPCN | US$16.39M | −US$5.07M | n/a | −1.4× | n/a | 0.8× | −249.2% | 0.0× | 1.18 |
| MaaT Pharma · EURONEXT:MAAT | US$16.11M | US$23.36M | n/a | 4.7× | n/a | n/a | −686.6% | n/a | n/a |
| Elicera Therapeutics AB · OMXSTO:ELIC | US$16.09M | US$10.40M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | n/a |
| Atossa Therapeutics, Inc. · NASDAQ:ATOS | US$15.92M | −US$4.66M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.87 |
| Quoin Pharmaceuticals. Ltd · NASDAQ:QNRX | US$15.76M | −US$17.43M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 0.68 |
| Celularity Inc. · NASDAQ:CELU | US$15.02M | US$50.46M | n/a | 2.7× | n/a | n/a | −117.3% | n/a | 1.47 |
| Median of the others | US$16.25M | US$11.52M | 3.7× | 1.7× | −213.8% | 0.0× | 1.18 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.76 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Tiago Reis Marques | Chief Executive Officer and Director |
| Daniel Schneiderman | Chief Financial Officer |
| Patrick Gaynes | Corporate Communications |
| Kartik Krishnan | Chief Medical Officer |
| Lawrence Steinman | Executive Chairman and Co-Founder |
Board
| Director | Role |
|---|---|
| Lawrence Steinman | Executive Chairman and Co-Founder |
| Alfred Novak | Director |
| Daniel R. Weinberger | Director |
| Emer Leahy | Director |
| Simon Dumesnil | Director |
| Tiago Reis Marques | Chief Executive Officer and Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 · After close | −4.2% |
| Q2 2026 | Aug 14, 2026 · After close | −0.6% |
| Q1 2026 | Jun 3, 2026 | −3.9% |
| Q4 2025 | Mar 30, 2026 · After close | +3.8% |
| Q3 2025 | Nov 13, 2025 | +2.1% |
| Q2 2025 | Aug 14, 2025 | −2.1% |
| Q1 2025 | May 15, 2025 | +0.1% |
| Q4 2024 | Mar 24, 2025 | +0.8% |
| Q3 2024 | Dec 27, 2024 · After close | +8.1% |
| Q2 2024 | Aug 11, 2024 · After close | −1.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · After close | 0.0% |
| Q4 2023 | Mar 28, 2024 · After close | 0.0% |
| Q3 2023 | Dec 29, 2023 · After close | |
| Q2 2023 | Aug 11, 2023 · After close | −1.6% |
| Q1 2023 | May 12, 2023 · After close | −1.1% |
| Q4 2022 | Mar 1, 2023 | +2.9% |
| Q3 2022 | Nov 14, 2022 · After close | −2.8% |
| Q2 2022 | Aug 15, 2022 · After close | −2.3% |
| Q1 2022 | May 16, 2022 · After close | +9.1% |
| Q4 2021 | Mar 30, 2022 · After close | −7.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 20 slides | September 2026 |
| IPO Roadshow (August 2021) | IPO roadshow | 17 slides | Aug 27, 2021 |
| IPO Roadshow (August 2021) | IPO roadshow | 17 slides | Aug 6, 2021 |
| IPO Roadshow (June 2021) | IPO roadshow | 15 slides | Jun 22, 2021 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock (or pre-funded warrants in lieu thereof) Closed: US$60M raised · US$0.75 a share · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Buyers: Vivo Capital; Janus Henderson Investors; Coastlands Capital; Columbia Threadneedle Investments; Adage Capital Partners; Squadron Capital Management Use of proceeds: General corporate purposes, including research, clinical trials and working capital | Dec 2, 2025 |
| Public offering of common stock (or pre-funded warrants) with Series C and Series D warrants Closed: US$5M raised · US$1.4 a share · Warrants at US$1.4 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: General corporate purposes, including research, pre-clinical studies, clinical trials, licensing, acquisitions and working capital | May 7, 2025 |
| Warrant exercise of series D warrants Closed: US$1.3M raised · US$1.4 a share | May 7, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$5.00 a unit on Sep 14, 2021.
- Price
- US$5.00 a unit
- Units offered
- 4,800,000 units
- Offering size
- US$24 million
- Underwriters' option
- Up to 720,000 more units
- Listing
- KTTA on the Nasdaq Capital Market
- Underwriter
- EF HUTTON
- Units delivered
- On or about Sep 17, 2021
Steps
| Step | When |
|---|---|
| Filed publicly | Apr 13, 2021 |
| Amended 6 times | Newest Sep 13, 2021 |
| Shares registered with an exchange | Sep 13, 2021 |
| Declared effective by the SEC | Sep 14, 2021 |
| Final prospectus, with the price | Sep 16, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 16, 2021 |
| EFFECT · Notice that a registration is effective | Sep 14, 2021 |
| S-1MEF · Registration of more shares for the same offering | Sep 14, 2021 |
| CERT · Exchange's certificate of listing | Sep 14, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 13, 2021 |
| S-1/A · Registration statement, amended | Sep 13, 2021 |
| CORRESP · Letter to the SEC | Sep 10, 2021 |
| CORRESP · Letter to the SEC | Sep 10, 2021 |
| S-1/A · Registration statement, amended | Sep 10, 2021 |
| FWP · Free writing prospectus | Aug 27, 2021 |
All 25 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Aug 27, 2021 |
| CORRESP · Letter to the SEC | Aug 26, 2021 |
| UPLOAD · Letter from the SEC | Aug 11, 2021 |
| FWP · Free writing prospectus | Aug 6, 2021 |
| S-1/A · Registration statement, amended | Aug 6, 2021 |
| CORRESP · Letter to the SEC | Aug 5, 2021 |
| UPLOAD · Letter from the SEC | Jul 1, 2021 |
| FWP · Free writing prospectus | Jun 22, 2021 |
| S-1/A · Registration statement, amended | Jun 22, 2021 |
| CORRESP · Letter to the SEC | Jun 21, 2021 |
| UPLOAD · Letter from the SEC | Jun 16, 2021 |
| CORRESP · Letter to the SEC | Jun 4, 2021 |
| S-1/A · Registration statement, amended | Jun 4, 2021 |
| UPLOAD · Letter from the SEC | May 10, 2021 |
| S-1 · Registration statement | Apr 13, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Sep 16, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 486.6K | 486.6K | 15.1K | |
| Cost of revenue | 662.6K | 649.0K | 648.5K | 113.2K | 17.3K | |
| Gross profit | -662.6K | -649.0K | -648.5K | -5.09K | -2.21K | |
| Research and development | 7.98M | 7.20M | 8.10M | 2.67M | 0 | |
| Selling, general and administrative | 12.9M | 7.05M | 7.88M | 9.92M | 4.51M | |
| Operating income | -20.9M | -14.2M | -16.0M | -12.6M | -4.51M | -61.5K |
| Depreciation and amortization | 32.4K | 18.9K | 18.3K | 5.09K | 1.38K | 61.5K |
| EBITDA | -20.8M | -14.2M | -16.0M | -12.6M | -4.51M | 0 |
| Interest expense | 102 | 508 | 0 | |||
| Income before tax | -20.4M | -13.9M | -15.5M | -11.7M | -2.17M | -61.5K |
| Income tax | 453.9M | -880.0K | 508 | -61.5K | ||
| Net income | -20.4M | -13.9M | -16.0M | -13.9M | -2.17M | -61.5K |
| Earnings per share, basic | -2.91 | -12.69 | -0.42 | -1.76 | -0.21 | -0.09 |
| Earnings per share, diluted | -2.91 | -12.69 | -0.42 | -1.76 | -0.21 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 55.2M | 6.92M | 16.3M | 33.1M | 53.0M | 243.7K |
| Short-term investments | 6.92B | |||||
| Receivables | 40.5K | 302.1K | ||||
| Inventory | -40.5K | 1 | ||||
| Current assets | 56.5M | 7.37M | 16.7M | 34.1M | 53.3M | 248.0K |
| Property, plant and equipment | 122.3K | 141.2K | 125.2K | 20.1K | ||
| Goodwill | 0 | 1.26M | 1.26M | 1.26M | 0 | |
| Total assets | 60.2M | 16.1M | 26.1M | 45.2M | 53.3M | 248.0K |
| Accounts payable | 1.12M | 2.55M | 1.48M | 447.3K | 6.60K | |
| Current liabilities | 4.97M | 1.12M | 2.63M | 1.88M | 447.3K | 6.60K |
| Total debt | 81.7K | 504.4K | ||||
| Total liabilities | 5.02M | 1.28M | 2.72M | 2.68M | 1.90M | 6.60K |
| Shareholders' equity | 55.2M | 14.8M | 23.4M | 42.5M | 51.4M | 241.4K |
| Shares outstanding | 23.1M | 1.39M | 1.04M | 1.30M | 23.0M | 688.9K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -15.2M | -13.9M | -12.8M | -14.6M | -3.17M | -38.7K |
| Capital spending | 0 | -2 | -34.3K | -107.1K | -21.5K | -1 |
| Free cash flow | -15.2M | -13.9M | -12.8M | -14.7M | -3.20M | -38.7K |
| Cash from investing | 11.0K | 75.2K | -2.06M | -21.5K | -21.5K | |
| Cash from financing | 63.5M | 4.52M | -3.73M | -3.21M | 55.9M | 282.3K |
| Dividends paid | -359.7M | |||||
| Share buybacks | 0 | -3.73M | -3.21M | 0 | ||
| Change in cash | 48.3M | -9.41M | -16.8M | -19.8M | 52.7M | 243.7K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 16, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 6, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 16, 2026 | Current report | SEC |
| 25-NSE | Sep 16, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 9, 2026 | Meeting outcome | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Aug 21, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Aug 7, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Aug 7, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 31, 2026 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Jul 29, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 1, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 23, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 5, 2026 | Insider trade | SEC |
| 8-K · Current report | May 4, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 22, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Apr 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 8, 2026 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 30, 2026 | Annual report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 20, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 12, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Jan 30, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 28, 2026 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Jan 28, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Jan 26, 2026 | Offer document | SEC |
| DEF 14A · Proxy statement | Dec 29, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Dec 19, 2025 | Meeting notice | SEC |
| 8-K · Current report | Dec 15, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 8, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 5, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 5, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 2, 2025 | Material contract | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 424B4 · Prospectus | Dec 1, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 1, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 26, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 26, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Nov 26, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 25, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Nov 24, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 24, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 21, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 21, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 21, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 21, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 19, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 19, 2025 | Other filings | SEC |
| S-1 · Registration statement | Nov 18, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 27, 2025 | Management or board change | SEC |
| 8-K · Current report | Sep 16, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Sep 9, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 3, 2025 | Management or board change | SEC |
| UPLOAD · Letter from the SEC | Sep 2, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Aug 27, 2025 | Offer document | SEC |
| DRSLTR · Letter to the SEC with a draft | Aug 27, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Jul 24, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Jul 24, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jul 14, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jul 11, 2025 | Current report | SEC |
| 8-K · Current report | Jun 27, 2025 | Current report | SEC |
| 8-K · Current report | Jun 20, 2025 | Current report | SEC |
| 424B5 · Prospectus | Jun 20, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | May 14, 2025 | Other filings | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 9, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 9, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 7, 2025 | Material contract | SEC |
| 424B4 · Prospectus | May 7, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | May 7, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 1, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 1, 2025 | Other filings | SEC |
| S-1 · Registration statement | May 1, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 25, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | Apr 14, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Apr 7, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 24, 2025 | Annual report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 6, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 424B5 · Prospectus | Nov 26, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 26, 2024 | Material contract | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Oct 15, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Oct 11, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Oct 10, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Oct 10, 2024 | Other filings | SEC |
| S-3 · Registration statement | Oct 7, 2024 | Offer document | SEC |
| 8-K · Current report | Sep 30, 2024 | Material contract | SEC |
| 8-K · Current report | Sep 26, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jun 26, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| ARS · Annual report to shareholders | May 28, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | May 28, 2024 | Meeting notice | SEC |
| 8-K · Current report | May 14, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 4/A · Change in ownership, amended | Apr 5, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Apr 5, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Apr 5, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Apr 5, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Apr 5, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Apr 5, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Apr 5, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Apr 3, 2024 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 29, 2024 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 28, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 28, 2024 | Annual report | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 18, 2024 | Current report | SEC |
| 8-K · Current report | Jan 2, 2024 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Dec 28, 2023 | Meeting notice | SEC |
| 8-K · Current report | Dec 28, 2023 | Current report | SEC |
| DEFA14A · Additional proxy material | Dec 19, 2023 | Meeting notice | SEC |
| 8-K · Current report | Dec 19, 2023 | Management or board change | SEC |
| DEFA14A · Additional proxy material | Nov 29, 2023 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Oct 26, 2023 | Annual report | SEC |
| DEF 14A · Proxy statement | Oct 26, 2023 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Oct 16, 2023 | Meeting notice | SEC |
| 8-K · Current report | Oct 13, 2023 | Current report | SEC |
| SC TO-I/A | Sep 14, 2023 | Acquisition or disposal | SEC |
| 8-K · Current report | Sep 14, 2023 | Current report | SEC |
| SC TO-I/A | Aug 24, 2023 | Acquisition or disposal | SEC |
| SC TO-I/A | Aug 21, 2023 | Acquisition or disposal | SEC |
| CORRESP · Letter to the SEC | Aug 21, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 15, 2023 | Other filings | SEC |
| SC TO-I/A | Aug 14, 2023 | Acquisition or disposal | SEC |
| 10-Q · Quarterly report | Aug 11, 2023 | Quarterly report | SEC |
| SC TO-I | Aug 9, 2023 | Acquisition or disposal | SEC |
| SC TO-C | Jul 20, 2023 | Other filings | SEC |
| 8-K · Current report | Jul 20, 2023 | Current report | SEC |
| 8-K · Current report | Jul 20, 2023 | Current report | SEC |
| 3 · Initial statement of ownership | Jul 3, 2023 | Insider trade | SEC |
| SC 13D · Big-stake notice | Jun 7, 2023 | Big-stake notice | SEC |
| 4/A · Change in ownership, amended | Jun 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2023 | Insider trade | SEC |
| 424B3 · Prospectus | Jun 6, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 6, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 1, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 19, 2023 | Other filings | SEC |
| DEL AM | May 17, 2023 | Other filings | SEC |
| S-3 · Registration statement | May 12, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | May 12, 2023 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Apr 20, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 17, 2023 | Other filings | SEC |
| 10-K/A · Annual report, amended | Apr 4, 2023 | Annual report | SEC |
| UPLOAD · Letter from the SEC | Apr 4, 2023 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 30, 2023 | Offer document | SEC |
| S-3 · Registration statement | Mar 30, 2023 | Offer document | SEC |
| 10-K · Annual report | Mar 30, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 10, 2023 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Feb 14, 2023 | Insider trade | SEC |
| 8-K · Current report | Jan 24, 2023 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 13, 2023 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Jan 10, 2023 | Big-stake notice | SEC |
This page holds 200 of 350 filings. Open Filings
Cap table
Built by 6ix from Pasithea Therapeutics Corp.’s releases · as of Dec 2, 2025
- Common shares
- 33,414,448
- Fully diluted
- 33,414,448
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 33,414,448 |
Warrants and options
| Lot |
|---|
| Warrants · US$1.40 · expire about May 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 33,414,448 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Lawrence Steinman Other companies: BioAtla, Inc. (Director · Since at least Dec 15, 2020); Forum Markets, Incorporated (Director · Since at least Nov 6, 2020) | Director · Since at least Sep 14, 2021 |
| Emer Leahy Other companies: Intensity Therapeutics, Inc. (CEO · Since at least Mar 6, 2024) | Director · Since at least Mar 1, 2024 |
| Alfred Novak | Director · Since at least Oct 24, 2025 |
| Daniel R. Weinberger | Director · Since at least Nov 4, 2026 |
| Daniel Schneiderman | Chief Financial Officer · Since at least Nov 5, 2026 |
| Graeme Martin Currie | Chief Development Officer · Jul 3, 2023 – Mar 1, 2024 · Past |
| Kartik Krishnan | Chief Medical Officer · Since at least Nov 3, 2026 |
| Luca Rastelli | Since at least Nov 4, 2026 |
| Patrick Gaynes | Corporate Communications · Since at least Nov 3, 2026 |
| Simon Dumesnil | Director · Since at least Nov 15, 2022 |
All 11 people
| Person | Seat |
|---|---|
| Tiago Reis Marques | Chief Executive Officer and Director · Since at least Nov 3, 2026 |
Log in to ask 6ix AI your own questions about Pasithea Therapeutics Corp.